Serum Institute's Covovax anticipated launch by September, says CEO Adar Poonawalla
New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.
In August 2020, US-based vaccine maker Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and India.
"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #Covid-19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Poonawalla said in a tweet.
The development and commercialisation pact between Novavax and SII excludes major upper-middle and high-income countries, for which Novavax continues to retain rights.
In January this year, Poonawalla had said SII expected to launch Covovax by June 2021.
"Our partnership for a Covid-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch Covovax by June 2021!", Poonawalla had said in a tweet.
SII is already supplying AstraZeneca/Oxford Covid-19 vaccine, Covishield, in India and to other countries across the world.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.